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ABSTRACT
Objective: To determine the seroprevalence of varicella zoster in paediatric patients 
at a high risk of developing complications.
Design: A cross-sectional study.
Setting: Paediatric general wards at Kenyatta National Hospital.
Subjects: Children with malignancies, severe malnutrition and were HIV positive.
Interventions: The sample size was calculated at 147 subjects. Venous samples were 
tested for varicella zoster virus (VZV) antibodies using enzyme immunosorbent 
assay (ELISA) technique at Kenya Medical Research Institute (KEMRI) laboratories, 
The data were anaIysed using the SPSS software and presented in form of tables 
and graphs. The prevalence of VZV antibodies was determined and 95% confidence 
interval computed.
Results: The overall seroprevalence of VZV antibodies in the three groups of children 
studied was 23.6% (95% CI= 17.4, 29.8), The seroprevalence of VZV antibodies in those 
with malignancies and severe malnutrition was 24.1 and 25.0% respectively. About 
22% of HIV positive children had protective levels of VZV antibodies. Though the 
seroprevalence increased with age, it was not significantly associated with area of 
residence, size of residence, family size or income.
Conclusions: The low prevalence of protective VZV antibodies among children with 
severe malnutrition, malignancies and HIV infection children at Kenyatta National 
Hospital warrants routine immunisation of the high-risk population.
INTRODUCTION
Varicella first became prominent in Europe during 
the sixteenth century and was called chickenpox in 
1694 and varicella by Vogel in 1765 (1). Varicella zoster 
virus is the aetiologic agent of two human diseases, 
varicella and herpes zoster (2).
 There is considerable interest in the disease due 
to epidemiological variations between geographic 
locations, especially between temperate and tropical 
regions of the world. Whereas in temperate countries, 
varicella is considered to be a childhood disease with 
almost universal seroconversion by early adolescence, 
in tropical countries, it is both a childhood and 
adulthood disease (3,4).
 There  is very scanty information on 
seroprevalance of VZV in Africa, and most of the 
information on tropical countries has come from 
Central America and South East Asia (4-6).
 Immuno-compromised  patients are  at 
significantly higher risk of developing varicella-
associated morbidity and mortality than their 
immuno-competent counterparts (7). Malignancies, 
m a l n u t r i t i o n  a n d  H I V  d i s e a s e  c a u s e 
 immuno-suppression, mainly affecting cell-mediated 
immunity. There appears to be some association 
between recovery from disease in the immuno-
compromised and a brisk VZV-specific cell-mediated 
immune response, as indicated by lymphocyte 
blastogenesis or lymphocyte-mediated cytotoxicity 
at the time of initial evaluation. These patients have a 
mortality rate ranging from seven to 20% with a very 
high incidence of visceral dissemination (8-11).
 An attack of varicella induces both cellular and 
humoral immune responses to VZV. Although the 
presence of either may be used to indicate immunity 
to varicella, this is most frequently determined by 
measuring the humoral response. The tests used 
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include complement fixation, neutralisation, immune 
adherence haemagglutination, fluorescent antibody 
to membrane antigen (FAMA), radioimmunoassay, 
and enzyme-linked immuno-sorbent assay (ELISA). 
The ELISA technique is relatively simple and the 
laboratory equipment required is minimal with 
sensitivity of about 97% and specificity of 94%. A live 
attenuated varicella vaccine has been developed and 
is immunogenic with a good safety profile in both 
healthy and high-risk individuals (12).
 There are concerns about safety and 
efficacy in the use of live attenuated vaccines in 
immunocompromised patients particularly those 
with AIDS. Data from the 1999 Paediatric AIDS 
Clinical Trial Group indicated that the vaccine was 
immunogenic, effective and safe.
 Chickenpox is thus an important cause of 
morbidity and mortality in immuno-compromised 
patients. Although this group of patients would 
benefit from the vaccine, the cost may make it 
impossible for all of them to be vaccinated. This study 
aims at determining the seroprevalence of varicella 
in the high-risk children population as an indicator 
of its susceptibility to the infection.
MATERIALS AND METHODS
The study objective was to determine the 
seroprevalence of varicella-zoster antibodies in 
children with malignancies, severe malnutrition and 
HIV infection at Kenyatta National Hospital.
 This was a hospital based cross-sectional study 
carried out in paediatric general wards at Kenyatta 
National Hospital. KNH is the national tertiary 
hospital and teaching hospital for the University 
of Nairobi, Faculty of Medicine. It is also the main 
in-patient hospital for the low and middle - income 
society in Nairobi and its environments. There are 
four paediatric general wards at the hospital and each 
of these wards admits approximately 30-50 patients 
daily.
Case definition:
(i) Malignancy: based on bone marrow cytology for 
leukemia, fine needle aspirate or a biopsy for 
lymphoma and biopsy for solid tumours.
(ii) Severe malnutrition: defined using Wellcome 
classification as children less than 80% of the 
expected body weight with oedema or less than 
60% of expected body weight with or without 
oedema.
(iii) HIV positivity: based on positive ELISA results 
for HIV infection.
Study population: All children who fulfilled the criteria 
outlined below were selected consecutively.
Inclusion criteria:
(i) Age between one to 12 years accompanied by 
either parent or guardian.
(ii) Diagnosed with malignancy using predefined 
criteria.
(iii) Diagnosed with severe malnutrition.
(iv) HIV positive children diagnosed using ELISA. 
(v) Written consent by a parent or guardian before 
recruitment to the study.
Exclusion criteria:
Sample size was computed for each of the three 
groups, that is, children with malignancies, those 
with severe malnutrition and HIV positivity. This was 
done to give the study enough power to sub-analyse 
besides computing the overall prevalence.
The sample size was determined as follows  
n=(Z1-α/2)2P(1-P)/δ2
Where:
n = minimum sample size
Z1-α/2 = the table value for standard normal 
distribution at 5% significance level = 
1.96
δ  =  degree of precision = 10% 
α
 
=  significance level set at 5%
p  =  estimated prevalence of children with VZV 
antibodies.
  P was estimated from studies carried out 
in West Indies, Singapore, Phillipines and 
Western India where the prevalence of 
children with protective antibodies against 
varicella ranged from 10 to 20%, therefore 
a mean of 15% was used.
n  =  1.962 X 0.15 x 0.85/0.12
 =  49 was the minimum sample size for each 
of the three groups involved.
Study procedure:
Clinical procedures: The investigator visited the 
paediatric general wards daily from 8:00am to 
12:00pm and consequently identified eligible patients 
by going through the patients’ clinical records. The 
primary diagnosis was confirmed to make sure it 
conformed to the case definition and the patient 
fulfilled the inclusion criteria.
 After obtaining an informed written consent, 
a structured questionnaire, was then administered. 
Information collected included age, sex, previous 
admissions, size of family, number of rooms in the 
house and monthly family income. The patients were 
recruited consecutively in until they reached the 
minimum sample size for each of the three groups.
A venous sample of 2ml was obtained in a sterile 
procedure and 30 minutes allowed for clotting.
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 Serum was then extracted and placed into plastic 
vacutainers. Serum samples were then transferred to 
KEMRI laboratories immediately where they were 
stored at -20°C until tested.
Laboratory procedures: VZV antibodies were measured 
by enzyme linked immuno-sorbent assay (ELISA) 
used to measure VZV specific IgG. This was done at 
KEMRI laboratories. A commercial kit by the name of 
Trinity Biotech Captia VZV IgG ELISA, which has a 
sensitivity of 97% and a specificity of 94% compared 
against fluorescent antibody to membrane antigen 
assay as the standard. For each serum sample tested, 
immune status ratio (ISR) value was calculated by a 
formula provided by kit manufacturers using optical 
density against the cut-off value. Value of greater 
than 0.9 were considered negative and indicated 
susceptibility to VZV infection.
Ethical consideration: Permission to carry out the study 
was sought from the KNH Research and Ethical 
Committee. There was no cost incurred by the parent 
or guardian in the transport or processing of the serum 
specimen. An informed written consent was taken 
from the parent/guardian of the children enrolled 
in the study and they were given an appointment 
when the results were to be made available to them. 
If the child was found to be susceptible to chickenpox, 
he/she was offered varicella-zoster vaccine at no cost 
to the parents.
Analysis and data management: Data obtained were 
entered into the computer and analysed using 
the statistical package for social sciences software 
(SPSS). The seroprevalence of VZV antibodies was 
determined and 95% confidence interval levels 
(CI) computed, to get the proportion of children 
with protective antibodies, that is, immune status 
ratio of greater than 0.9, for both the overall study 
population and each of the groups defined by the 
primary diagnosis. Descriptive statistics including 
age, sex, area of residence, size of family, size of 
houses, monthly income and previous admissions 
were determined and used to describe the socio-
demographic characteristics of the study population. 
For categorical variables the chi-square test was used 
and P<0.05 was used for significance.
RESULTS
Data were collected in August and September 2003.
The study population consisted of 182 children whose 
age ranged from one to 12 years with a mode of 1-4 
years. The demographic characteristics of the study 
population are shown in Table 1.
Seroprevalence of VZV: The overall prevalence of 
protective varicella zoster antibodies was found to be 
23.6% (95% C I; 17.4-29.8). The prevalence of protective 
VZV antibodies in children with malignancies was 
found to be 24.1 % (95% Cl; 13.3- 34.9), whereas in 
those with severe malnutrition it was 25.0% (95% CI; 
14.1- 36.0). HIV positive children had a seropositivity 
rate of 21.9% (95% Cl 11.8-32.0).  Seropositivity of VZV 
increased significantly with age, with 17.5% of one to 
four year old children being seropositive as compared 
to 38.3% in children between the ages of eight and 12 
years (p = 0.012), (Table 2 and Figure 1).
Table 1
Socio-demographic characteristics of study population
                    Primary diagnosis   Total
    Severe malnutrition         HIV positive                       Malignancy 
  No. (%) No. (%) No. (%) 
Sex Male 31 52 35 54.7 38 65.5 104
 Female 29 48 29 45.3 20 34.5 78
 Total 60 64 58 182
Age  1-4 42 70 26 40.6 19 32.7 82
(years) 4-8 18 30 19 29.7 16 27.5 53
 8-12 - 19 29.7 23 39.7 42
 Total 60  64  58  182
Area of Within Nairobi 44 73.3 37 57.8 19 32.8 100
residence Outside Nairobi 16 26.7 27 42.2 39 67.2 82
 Total 60  64  58  182
Monthly <2000 44 73.3 52 81.3 35 60.3 144
income per 2000-5000 16 26.7 11 17.2 21 36.2 35
month (ksh) >5000 - 1 1.6 2 3.4 3
 Total 60  64  58  182
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Continuation of Table 1
Number of 
siblings 1 8 13 16 25 7 12.1 31
 2 20 33.3 35 54.7 31 53.4 86
 3 18 30 4 6.3 9 15.5 31
 4 9 15 6 9.4 7 12.1 22
 >4 5 8.3 3 4.7 4 6.9 12
 Total 60  64  58  182
Previous 
hospital Yes 13 21.7 22 34.4 17 29.3 52
admission No 47 78.3 42 65.6 41 70.7 130
 Total 60 64 58 182
Number of 
rooms 1 40 66.7 44 68.8 45 77.6 129
 2-4 16 26.7 19 29.7 10 17.2 45
 >4 4 6.7 1 1.6 3 5.2 8
 Total 60  64  58  182
 Table 2
Age related seroprevalence of VZV antibodies
Age (years)               Seropositive                            Seronegative                Total 
 No. (%) No. (%) No. (%)
1< 4 15 17.2 72 82.8 87 100
4< 8 11 20.8 42 79.2 53 100
8<12 17 40.5 25 59.5 42 100
 Total 43 139 182 100
X2 = 8.816; P = 0.012 
Table 3
Relationship between seroprevalence and socio-demographic characteristics
Socio-demographic characteristic                     Seropositive                       Seronegative  Total P-value
  No. (%) No. (%) 
Gender Male 24 23.1 80 76.9 104 0.840
 Female 19 24.4 59 75.6 78 
 Total 43  139  182 
Previous hospital Yes 16 30.8 36 69.2 52 0.151
admissions No 27 20.8 103 79.2 136 
 Total 43  139  182 
Area of residence Nairobi 24 24 76 76 100 0.896
 Outside Nairobi 19 23.2 63 76.8 82 
 Total 43  139  182 
Monthly family income <2000 28 21.4 103 78.6 131 
 2000-5000 14 29.2 34 70.8 48 
 >5000 1 33 2 67 3 0.519
 Total 43  139  182 
484 EAST AFRICAN MEDICAL JOURNAL October 2008 
Figure 1
Age related seroprevalence of VZV
There was no statistically significant difference in the 
seroprevalence of VZV in children by gender, previous 
hospital admissions, area of residence, monthly family 
income, number of siblings and number of rooms in 
the houses they resided in (Table 3).
DISCUSSION
This study revealed a very low overall prevalence of 
protective antibodies to VZV in all the three groups 
of children studied (23.6%), which mirrored that of 
many other countries in the tropics and less than 
those in the temperate countries. Various studies 
carried out in Thailand and Philippines showed the 
seroprevalence of VZV antibodies ranging between 
20% and 30% (3), while studies in West Indies, India 
(Velore) and Singapore showed a seroprevalence of 
less than 10% in children (13).
 In temperate countries, the prevalence of 
protective VZV antibodies is much higher. In 
surveys carried out in the United States of America, 
seroprevalence of VZV antibodies in children was 
more than 90% (3). Similar results were seen in studies 
carried out in Germany (13).
 This study showed a seroprevalence of 24.1% 
in children with malignancies. A study conducted in 
Yaounde, Cameroon on immunity to VZV in children 
with leukemia showed a seropositivity rate of 34%, 
whilst in Denmark; a seropositivity rate of 37% was 
found. A study in Israel to compare antibodies to 
VZV in children with Hodgkin’s disease and healthy 
children found the difference not to be statistically 
significant (14).
 The seroprevalence of VZV antibodies in 
children with HIV was found to be 21.9%. This 
correlates well with other studies conducted in 
Eritrea where and overall seropositivity rate was 
44% (5). This difference was thought to be due to the 
fact that the Eritrean study included adults as well. 
Other studies on children with HIV in Connecticut, 
USA showed 28% of the children were susceptible 
to varicella (7). In Madrid, Spain, a study conducted 
on HIV positive children admitted at a hospital 
showed 20% of the children were susceptible to VZV 
(10). There seems to be no significant difference in 
the prevalence of varicella infections between HIV 
positive children and their healthy counterparts. 
This was confirmed by a comparative study on the 
prevalence of VZV in conjunctiva of HIV positive 
and healthy children in Canada, which showed no 
significant difference (15).
 In severely malnourished children the 
seroprevalence of VZV antibodies was found to be 
25%. No studies have been conducted elsewhere 
to compute the susceptibility to varicella in this 
population, though it is postulated to reflect that in 
the general population.
 The differences in seroprevalence of VZV 
antibodies in temperate and tropical countries have 
been thought to be due to the weather differences. The 
year long high temperature, humidity, and absence 
of human clustering during winter are thought to 
reduce transmission rate (13). It is thought that high 
ambient temperature and humidity in the tropics 
decreases VZV transmission by inactivating the 
virus in the cutaneous lesions. Alternatively, it is 
possible that because of high prevalence of certain 
other childhood viruses in tropical countries, there 
is interference with the transmission of VZV and the 
age of varicella infection is postponed (16).





















Continuation of Table 3
Number of siblings 1 6 19.4 25 80.6 31 0.966
 2 20 23.3 66 76.7 86 
 3 8 25.8 23 74.2 31 
 4 6 27.3 16 72.7 22 
 >4 3 25 9 75 12 
 Total 43  139  182 
Number of rooms in the 1 29 22.5 100 77.5 129 0.847
house 2-4 12 26.7 33 73.3 45 
 >4 2 25 6 75 8 
 Total 43  139  182 
October 2008 EAST AFRICAN MEDICAL JOURNAL   485
 This study showed a seropositivity rate of 
23.1% and 24.4% for males and females respectively. 
This difference between the seroprevalence of VZV 
antibodies between males and females was not 
statistically significant (p=0.840). This observation was 
in keeping with the findings of studies in Sao Paulo, 
Brazil and Thailand, which showed a seroprevalence 
of 49.4% and 55.2% in males and females respectively, a 
difference that was not statistically significant (16).
 This study showed a gradual increase in 
the seropositivity rate of VZV antibodies in 
immunocompromised children between one year of 
age and 12 years, with seropositivity increasing from 
17.2% to 40.5% in 1-4 years to 8-12 years respectively. 
This difference was statistically significant (p = 0.012). 
This observation was in keeping with other studies 
from West Indies, Singapore, and Thailand (3). In India, 
the age related seroprevalence rate of VZV antibodies 
was 29% in the age group of 1-5 years, 51.1% in 5-10 
years and 71% in 11-15 years (4). A study in Thailand 
showed a seroprevalence of 20% in children aged 
between 1-4 years, which increased to 70% above the 
age of 15 years. In Singapore, VZV seroprevalence 
was noted to be 30% in children aged 1-5 years and 
56.7% in children aged 11-15 years (3). A study in UAE 
showed a seroprevalence of 45.8% in children less than 
10 years and 68% in those aged less than 20 years, a 
difference, which was statistically significant (17). 
These findings are thought to be due to the fact that as 
children grow, they tend to have more exposure to VZV 
thus more chances of developing the disease. Varicella 
is considered a pre-school disease in countries with 
temperate climates and a childhood and adulthood 
disease in tropical areas. This is attributed to the year 
long high temperature and humidity, and the absence 
of human clustering during winter.
 There was a slightly increased albeit not 
statistically significant seropositivity of VZV antibodies 
in children who had been admitted previously (30.8%) 
as compared to those not previously admitted at KNH 
(20.8%) (p = 0.151). An increase in seropositivity in 
children with a history of previous hospital admissions 
was anticipated due to exposure to varicella whilst 
in the wards and the effects of human clustering as 
it happens in institutions.
 In this study, children living within Nairobi, 
which is an urban area, had a seroprevalence of 24.0% 
and those living outside Nairobi had a seroprevalence 
of 23.2%. This difference was not statistically 
significant (p = 0.896). Epidemiological comparisons 
between rural and urban populations have been 
documented in West Bengal, India, where nearly all 
adults in the urban area were immune and all rural 
adults were susceptible to varicella infection (16). A 
study in Thailand showed no significant difference 
in the overall seroprevalence of VZV between rural 
and urban population, but in southern states of the 
country, the seroprevalence was significantly lower 
in rural areas (16). This finding was thought to be due 
to high population densities in urban areas, which 
may partially overcome the transmission-interrupting 
effect of a tropical climate. This phenomenon was not 
evident in our study probably due to the fact that the 
population density of Nairobi is much less than that of 
the city of Calcutta, West Bengal and the temperature 
and humidity in Nairobi is markedly lower than 
those encountered in Calcutta where the highest 
temperatures are about 38°C. These differences blunt 
the effect of urban living in the transmission of VZV 
as was seen in the northern states of Thailand.
 There was a slight increase in the seropositivity 
of VZV antibodies in children who came from families 
with a higher monthly income (33.3%), as compared 
to those from a lower monthly income (21.4%). 
This difference was not found to be statistically 
significant (p= 0.519). These results mirrored those 
in Eritrea, where a tribe called the Rashaida, which 
has a low socio-economic status, was found to have 
a significantly lower seroprevalence than the rest 
of the population (5). In Israel though, in children 
with Hodgkin’s disease, no statistical difference 
was found in the seroprevalence of VZV antibodies 
between those children from affluent backgrounds 
and those of a lower socio-economic status (14). 
These differences in the seroprevalence between 
children of different socio-economic backgrounds 
as seen in some studies is thought to be due to the 
fact that children from richer families tend to go to 
schools earlier, are then exposed to the virus earlier 
with clustering in classrooms making transmission 
easier.
 This study showed that the number of rooms 
in houses the children living in did not make a 
significant difference in the seroprevalence of VZV 
(p = 0.847). This finding was surprising as children 
living in smaller houses were expected to have a 
higher seropositivity rate due to enhanced clustering 
and thus transmission of VZV. 
 This study showed a VZV seropositivity rate 
of 27.3% in children who lived in families with four 
children as compared to 19.4% in those with one 
child. This difference was not statistically significant 
(p = 0.966). It was thought that larger families would 
enhance early exposure and transmission of varicella, 
which is a highly infectious disease with secondary 
infection rate of 90-100%. In our set-up though, this 
factor does not seem to be playing a significant role 
in transmission mechanics of VZV.
 Illnesses like severe malnutrition, malignancies, 
use of chemotherapy for the treatment and HIV 
infection cause immuno-suppression by affecting 
the cell-mediated immunity. A study conducted by 
Gershon et al (18) showed that there is an association 
between recovery from varicella infection in the 
immuno-compromised and a brisk VZV-specific 
cell-mediated immune response.
 Patients with malignancies receiving anticancer 
therapy at St. Judes Children Research Hospital 
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were found to have visceral dissemination in 32% 
after VZV infection, and had a mortality rate of 
seven (7%). A study at Sizwe Tropical Hospital in 
Reinfontein, South Africa showed a mortality rate 
of 43% in children with HIV disease who developed 
chickenpox (18).
 These complications could be prevented using 
a live-attenuated varicella vaccine. This is a highly 
immunogenic vaccine with a seroconversion rate 
ranging from 92.2% to 98.7% in healthy children and 
83.7% to 92.1% in children with underlying disease 
(19, 20). It has also shown to have 98% vaccine 
efficacy.
 The vaccine is indicated for all healthy 
individuals older than 12 months, who are susceptible 
to varicella, seronegative children who are at high 
risk of complications, such as patients undergoing 
chemotherapy, severe malnutrition and HIV positive 
children. It is also indicated for susceptible women of 
childbearing age to prevent foetal varicella syndrome 
and in closed societies like institutions.
 In developing countries it is not feasible to 
recommend vaccination of all children. Since 
the cost of the vaccine is more than the average 
monthly income of majority of families in the study 
population, it would only be practical to vaccinate 
the immunocompromised patients since the risk of 
mortality and morbidity is the highest in this group. 
Given that the seroprevalence of VZV ranges from 
17.2% to 40.5% in 1-4 years to 8-12 years old children 
respectively, it would be appropriate to vaccinate 
immunocompromised patients soon after one year 
of age or on first contact. It is hoped that this study 
will contribute to the prevention of chickenpox in 
this high-risk population.
In conclusion, we found overall prevalence of 
protective VZV antibodies (23.6%) among children 
with HIV infection, severe malnutrition and 
malignancies admitted at KNH paediatric wards to be 
relatively low. This was comparatively lower than the 
seroprevalence in countries with temperate climates 
and mirrors the situation in other tropical countries. 
The prevalence of protective VZV antibodies was 
not dependent on sex, area of residence, family size, 
family income, previous admissions but increases 
significantly with advancing age (p = 0.012).
 Vaccination of children with malignancies, 
severe malnutrition and HIV infection at Kenyatta 
National Hospital against varicella-zoster is highly 
recommended so as to reduce morbidity and mortality 
from varicella in this high- risk population.
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